HOWLWerewolf Therapeutics, Inc.

Nasdaq werewolftx.com


$ 2.13 $ 0.08 (3.88 %)    

Wednesday, 03-Jul-2024 12:59:34 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 2.14
$ 2.11
$ 0.00 x 0
$ 0.00 x 0
$ 2.05 - $ 2.24
$ 1.57 - $ 8.19
170,573
na
89.04M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 06-10-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 jmp-securities-reiterates-market-outperform-on-werewolf-therapeutics-maintains-12-price-target

JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $...

 hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

 werewolf-therapeutics-q1-eps-039-misses-035-estimate-sales-74200-miss-182m-estimate

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate ...

 werewolf-therapeutics-announces-wtx-124-clinical-abstract-accepted-for-presentation-at-the-2024-asco-annual-meeting

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic s...

 werewolf-therapeutics-presents-first-preclinical-data-highlighting-il-10-indukine-molecules-as-potential-therapy-for-inflammatory-bowel-disease-at-aai-annual-meeting

First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases

 werewolf-therapeutics-presents-preclinical-results-demonstrating-anti-tumor-effects-of-pro-inflammatory-cytokine-therapeutics-wtx-518-and-wtx-712-at-aacr-2024-annual-meeting

 WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regres...

 jmp-securities-initiates-coverage-on-werewolf-therapeutics-with-market-outperform-rating-announces-price-target-of-12

JMP Securities analyst Reni Benjamin initiates coverage on Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform rati...

 hc-wainwright--co-maintains-buy-on-werewolf-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Andres Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15 ...